Adenosine and Adenosine Receptors in Rheumatoid Arthritis

Melissa Padovan; Fabrizio Vincenzi; Marcello Govoni; Alessandra Bortoluzzi; Pier Andrea Borea; Katia Varani


Int J Clin Rheumatol. 2013;8(1):13-25. 

In This Article

Future Perspective

The role of adenosine in the modulation of chronic inflammation has been appreciated only in recent years. Interestingly, an overexpressed endogenous anti-inflammatory pathway may be a potential target therapy in RA. As a consequence, A2A and A3ARs agonists may represent a novel pharmacological treatment alone or in combination with traditional therapy, such as MTX. In the future, more preclinical and clinical studies are warranted to investigate the effect of selective A2A and A3ARs agonists in RA in order to translate these important findings into valuable benefits for RA patients. Adenosine pathway modulation may one day find its place in the therapeutic setting, especially in patients who are not fully responsive, at first as combination therapy, to obtain a more complete anti-inflammatory and, why not, atheroprotective effect.